Opinion|Videos|October 14, 2024
Exploring the Kidney-CHAMP Study
Key Takeaways
- The trial focused on improving cardiovascular risk management in type 2 diabetes through a coordinated care model involving healthcare systems.
- Interventions included educational sessions, feedback, and support for healthcare providers to enhance adherence to guideline-directed medical therapy.
A panel of experts explores the objectives and design of the COORDINATE-Diabetes trial, discussing its potential impact on the treatment paradigm for diabetes management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Tell us about Kidney-CHAMP study.
- What were the objectives of Kidney-CHAMP and how was the study designed?
- What interventions were provided?
- What were the results of the study?
- What are future opportunities to improve CRM care based on this study?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
3
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5